{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:26:20Z","timestamp":1785590780712,"version":"3.56.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.clinthera.2005.08.009","type":"journal-article","created":{"date-parts":[[2005,10,2]],"date-time":"2005-10-02T11:07:49Z","timestamp":1128251269000},"page":"1144-1163","source":"Crossref","is-referenced-by-count":43,"title":["Telithromycin: The first ketolide antimicrobial"],"prefix":"10.1016","volume":"27","author":[{"given":"Megan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3A","key":"10.1016\/j.clinthera.2005.08.009_bib1","first-page":"39S","article-title":"Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern","volume":"117","author":"File","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2005.08.009_bib2","first-page":"1","article-title":"Deaths: Final data for 2002","volume":"53","author":"Kochanek","year":"2004","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.clinthera.2005.08.009_bib3","unstructured":"National Center for Health Statistics. Faststats A to Z. Pneumonia. Available at: http:\/\/www.cdc.gov\/nchs\/fastats\/pneumonia.htm. Accessed November 29, 2004."},{"key":"10.1016\/j.clinthera.2005.08.009_bib4_1","series-title":"Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2002","year":"2004"},{"issue":"222","key":"10.1016\/j.clinthera.2005.08.009_bib4_2","volume":"10","year":"2004","journal-title":"Vital Health Stat"},{"key":"10.1016\/j.clinthera.2005.08.009_bib5","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199512143332408","article-title":"Community-acquired pneumonia","volume":"333","author":"Bartlett","year":"1995","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2005.08.009_bib6","doi-asserted-by":"crossref","first-page":"380S","DOI":"10.1378\/chest.117.5_suppl_2.380S","article-title":"Infectious etiology of acute exacerbations of chronic bronchitis","volume":"117","author":"Sethi","year":"2000","journal-title":"Chest"},{"issue":"Suppl 3A","key":"10.1016\/j.clinthera.2005.08.009_bib7","first-page":"3S","article-title":"Streptococcus pneumoniae: Epidemiology and patterns of resistance","volume":"117","author":"Jacobs","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2005.08.009_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/374052","article-title":"Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998\u20132002)","volume":"36","author":"Karlowsky","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0149-2918(04)90054-9","article-title":"Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: Findings from the PROTEKT US study, 2000\u20132001","volume":"26","author":"Stratton","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.08.009_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-0711-3-15","article-title":"Activity of telithromycin and comparators against bacterial pathogens isolated from 1,336 patients with clinically diagnosed acute sinusitis","volume":"3","author":"Dohar","year":"2004","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.clinthera.2005.08.009_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/40.1.85","article-title":"Ketolides lack inducibility properties of MLS(B) resistance phenotype","volume":"40","author":"Bonnefoy","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","article-title":"The macrolideketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA","volume":"31","author":"Hansen","year":"1999","journal-title":"Mol Microbiol"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2005.08.009_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.0070s3011.x","article-title":"Structure-activity relationships of ketolides vs. macrolides","volume":"7","author":"Douthwaite","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl T1","key":"10.1016\/j.clinthera.2005.08.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/48.suppl_2.1","article-title":"Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site","volume":"48","author":"Douthwaite","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib15","unstructured":"Ketek [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc; 2004."},{"key":"10.1016\/j.clinthera.2005.08.009_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1046\/j.1365-2958.2001.02438.x","article-title":"Erythromycin inhibition of 50S ribosomal subunit formation in Escherichia coli cells","volume":"40","author":"Usary","year":"2001","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.clinthera.2005.08.009_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00284-002-3710-0","article-title":"Telithromycin inhibition of protein synthesis and 50S ribosomal subunit formation in Streptococcus pneumoniae cells","volume":"45","author":"Champney","year":"2002","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.clinthera.2005.08.009_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.39.3.577","article-title":"Erythromycin resistance by ribosome modification","volume":"39","author":"Weisblum","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/jac\/43.4.559","article-title":"Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin","volume":"43","author":"Rosato","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jinf.2004.03.009","article-title":"Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections","volume":"49","author":"Low","year":"2004","journal-title":"J Infect"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2005.08.009_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1469-0691.2001.00048.x","article-title":"Microbiological profile of telithromycin, the first ketolide antimicrobial","volume":"7","author":"Felmingham","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2005.08.009_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.45.3.789-793.2001","article-title":"In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species","volume":"45","author":"Jalava","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/dkg359","article-title":"Comparative activity of telithromycin against typical community-acquired respiratory pathogens","volume":"52","author":"Buxbaum","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/dkh178","article-title":"Comparative in vitro activity of telithromycin against macrolideresistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae","volume":"53","author":"Walsh","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl S1","key":"10.1016\/j.clinthera.2005.08.009_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkf806","article-title":"Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999\u20132000 study","volume":"50","author":"Farrell","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2005.08.009_bib27","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1086\/382687","article-title":"Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: Molecular mechanisms and resistance phenotypes","volume":"38","author":"Edelstein","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib28","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1128\/AAC.41.10.2251","article-title":"mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae","volume":"41","author":"Tait-Kamradt","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.48.5.1882-1884.2004","article-title":"Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(03)00150-X","article-title":"In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis","volume":"22","author":"Kucukbasmaci","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2005.08.009_bib31","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1128\/AAC.46.9.2963-2968.2002","article-title":"Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia","volume":"46","author":"Kozlov","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl S1","key":"10.1016\/j.clinthera.2005.08.009_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkf808","article-title":"Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin","volume":"50","author":"Felmingham","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl S1","key":"10.1016\/j.clinthera.2005.08.009_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/dkf811","article-title":"Antimicrobial resistance among isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance program during 1999\u20132000","volume":"50","author":"Canton","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl S1","key":"10.1016\/j.clinthera.2005.08.009_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/dkf810","article-title":"The PROTEKT surveillance study: Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections","volume":"50","author":"Hoban","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib35","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1128\/AAC.45.11.3250-3252.2001","article-title":"In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae","volume":"45","author":"Okamoto","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib36","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.42.6.1520","article-title":"Susceptibilities of Legionella spp. to newer antimicrobials in vitro","volume":"42","author":"Schulin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/39.5.669","article-title":"In-vitro activity of ketolides against mycoplasmas","volume":"39","author":"Bebear","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/48.3.403","article-title":"In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae","volume":"48","author":"Miyashita","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib39","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1128\/AAC.42.6.1515","article-title":"In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae","volume":"42","author":"Roblin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.45.1.170-175.2001","article-title":"Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses","volume":"45","author":"Namour","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/46.5.741","article-title":"Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the orophryngeal and intestinal microflora","volume":"46","author":"Edlund","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000066766","article-title":"Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers","volume":"48","author":"Perret","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2005.08.009_bib43","series-title":"Briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting","author":"Aventis Pharmaceuticals. Ketek\u2122 (telithromycin)","year":"2003"},{"key":"10.1016\/j.clinthera.2005.08.009_bib44","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/0036554021000026958","article-title":"Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin","volume":"34","author":"Bhargava","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib45","doi-asserted-by":"crossref","first-page":"P49","DOI":"10.1016\/j.clpt.2004.12.081","article-title":"The bioequivalence of oral administration of telithromycin tablets crushed versus swallowed whole in healthy adult subjects","volume":"77","author":"Lippert","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2005.08.009_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1469-0691.2001.00051.x","article-title":"Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: Focus on telithromycin","volume":"7","author":"Drusano","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2005.08.009_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/dkh068","article-title":"Tissue kinetics of telithromycin, the first ketolide antibacterial","volume":"53","author":"Muller-Serieys","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/47.6.837","article-title":"Lung concentrations of telithromycin after oral dosing","volume":"47","author":"Khair","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib49","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.46.3.917-921.2002","article-title":"Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers","volume":"46","author":"Kadota","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib50","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.45.11.3104-3108.2001","article-title":"Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647)","volume":"45","author":"Muller-Serieys","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib51","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/AAC.42.8.1944","article-title":"Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils","volume":"42","author":"Vazifeh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib52","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1128\/AAC.45.6.1794-1798.2001","article-title":"Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils","volume":"45","author":"Mandell","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib53","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkf062","article-title":"Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration","volume":"49","author":"Namour","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib54","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0924-8579(03)00050-5","article-title":"Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy","volume":"21","author":"Gehanno","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl S2","key":"10.1016\/j.clinthera.2005.08.009_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/dkf510","article-title":"Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract","volume":"50","author":"Soriano","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib56","series-title":"40th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetic and clinical studies of a new ketolide antimicrobial, telithromycin (HMR 3647), in otorhinolaryngology","author":"Miyamoto","year":"2000"},{"key":"10.1016\/j.clinthera.2005.08.009_bib57","series-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Telithromycin concentration in middle ear fluid in children with acute otitis media or otitis media with effusion","author":"Cantalloube","year":"2004"},{"key":"10.1016\/j.clinthera.2005.08.009_bib58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0091270003262952","article-title":"Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment","volume":"44","author":"Shi","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.08.009_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0924-8579(03)00128-6","article-title":"Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment","volume":"22","author":"Cantalloube","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2005.08.009_bib60","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/AAC.44.7.1846-1849.2000","article-title":"In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (telithromycin) against Chlamydia pneumoniae","volume":"44","author":"Gustafsson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/AAC.45.1.23-29.2001","article-title":"Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens","volume":"45","author":"Odenholt","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/41.2.149","article-title":"Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect","volume":"41","author":"Boswell","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib63","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jac\/dkh475","article-title":"Pharmacodynamic activity of telithromycin against macrolidesusceptible and macrolide-resistant Steptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations","volume":"54","author":"Zhanel","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib64","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: Future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib65","series-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"In vitro time-kill pharmacodynamics of telithromycin against macrolide resistant S. pneumoniae isolates possessing ribosomal mutations","author":"Al-Lahham","year":"2004"},{"key":"10.1016\/j.clinthera.2005.08.009_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/46.1.51","article-title":"Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila","volume":"46","author":"Baltch","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2005.08.009_bib67","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1345\/aph.1E218","article-title":"The important of appropriate antimicrobial dosing: Pharmacokinetic and pharmacodynamic considerations","volume":"38","author":"Preston","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14656566.5.2.229","article-title":"Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: Application to telithromycin","volume":"5","author":"Nicolau","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib69","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.44.6.1749-1753.2000","article-title":"Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004","volume":"44","author":"Munckhof","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib70","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/jac\/dkg437","article-title":"Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 gram-positive cocci","volume":"52","author":"Jacobs","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib71","series-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Post-antibiotic effects (PAE) of GW 773546 and GW 708408 compared to other agents against nine S. pneumoniae and seven H. influenzae strains","author":"Pankuch","year":"2004"},{"key":"10.1016\/j.clinthera.2005.08.009_bib72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/42.6.703","article-title":"The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent","volume":"42","author":"Boswell","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib73","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.42.4.945","article-title":"Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)","volume":"42","author":"Barry","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib74","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.clinthera.2005.08.009_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2005.08.009_bib76","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2005.08.009_bib78","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1469-0691.2003.00678.x","article-title":"Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia","volume":"9","author":"Carbon","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2005.08.009_bib79","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"Van Rensburg","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2005.08.009_bib80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10096-004-1152-2","article-title":"Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila","volume":"23","author":"Carbon","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib82","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/rmed.2002.1382","article-title":"Telithromycin is as effective as amoxicillin\/clavulanate in acute exacerbations of chronic bronchitis","volume":"96","author":"Aubier","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2005.08.009_bib83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/147323000303100301","article-title":"Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis","volume":"31","author":"Zervos","year":"2003","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clinthera.2005.08.009_bib84","series-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Comparison of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial","author":"Mandell","year":"2003"},{"key":"10.1016\/j.clinthera.2005.08.009_bib85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000057670","article-title":"Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis","volume":"48","author":"Roos","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2005.08.009_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/014556130308200812","article-title":"Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin\/clavulanic acid for 10 days in acute maxillary sinusitis","volume":"82","author":"Luterman","year":"2003","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.clinthera.2005.08.009_bib87","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/194589240301700610","article-title":"A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis","volume":"17","author":"Buchanan","year":"2003","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.clinthera.2005.08.009_bib88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.otohns.2004.05.010","article-title":"Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis","volume":"131","author":"Ferguson","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clinthera.2005.08.009_bib89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14740338.1.2.121","article-title":"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval","volume":"1","author":"Iannini","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2005.08.009_bib90","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mcp.2003.4","article-title":"Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects","volume":"73","author":"Demolis","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.08.009_bib91","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1086\/379617","article-title":"Telithromycin and myasthenia gravis","volume":"37","author":"Nieman","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.08.009_bib92","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1345\/aph.1D567","article-title":"Potential interaction between telithromycin and warfarin","volume":"38","author":"Kolilekas","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.08.009_bib93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1345\/aph.1E496","article-title":"Verapamil toxicity resulting from a probable interaction with telithromycin","volume":"39","author":"Reed","year":"2005","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T21:40:43Z","timestamp":1683236443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0149291805001578"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.08.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}